CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) – Pipeline Review, H2 2016’, provides in depth analysis on CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) targeted pipeline therapeutics.

The report provides comprehensive information on the CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17)

The report reviews CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics and enlists all their major and minor projects

The report assesses CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC 2.7.11.17) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Allosteros Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) Overview 5

Therapeutics Development 6

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Products under Development by Stage of Development 6

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Products under Development by Therapy Area 7

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Products under Development by Indication 8

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Pipeline Products Glance 9

Early Stage Products 9

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Products under Development by Companies 10

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Products under Development by Universities/Institutes 12

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Molecule Type 16

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Companies Involved in Therapeutics Development 18

Allosteros Therapeutics Inc 18

Sumitomo Dainippon Pharma Co Ltd 19

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Drug Profiles 20

CNB-001 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

KN-93 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Small Molecule 2 to Inhibit CaM Kinase for Malaria - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecules to Inhibit CaMKII for Undisclosed Indication - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Dormant Projects 27

CaM Kinase (Ca2+/Calmodulin Dependent Protein Kinase or EC

2.7.11.17) - Discontinued Products 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30

List of Tables

List of Tables

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of Products under Development by Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Molecule Type, H2 2016 17

Pipeline by Allosteros Therapeutics Inc, H2 2016 18

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 19

Dormant Projects, H2 2016 27

Discontinued Products, H2 2016 28

List of Figures

List of Figures

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Molecule Types, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 16

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports